Myralis Pharma

myralis.com.br

Total dedication to life Innovative and modern in the pharmaceutical sector, the goal to be achieved is in line with what we propose to our clients and partners: always look forward. The reason? The health of thousands of people. Pioneering, Excellence and Technology in our Brands of Success. With a highly qualified Research and Development team, we are able to work together with our physicians, launching pioneering brands in the market. Our growth gives us the certainty of the path and enthusiasm to move forward. That is why we have evolved at a fast and constant pace, delivering innovative medicines not only for our own line but also for a network of partners.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

VEEVA DEVELOPMENT CLOUD SIMPLIFIES DRUG DEVELOPMENT IN THE INDUSTRY

Veeva Systems | May 21, 2021

news image

A growing number of life sciences companies are adopting Veeva Development Cloud applications from Veeva Systems in an industrywide shift to streamline drug development. quite 650 companies use Veeva Development Cloud applications today, and quite 250 are leveraging multiple Veeva Vault applications across functional areas to enable and connect drug development and manufacturing teams. Veeva Development Cloud brings together suites of unified applications for clinical, regulatory,...

Read More

Pharmacy Market

ANTARES PHARMA ANNOUNCES FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO®

Antares Pharma, Inc. | February 04, 2022

news image

Antares Pharma, Inc. a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted its New Drug Application resubmission for TLANDO®, an oral treatment for testosterone replacement therapy. The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March 28, 2022, under the Prescription Drug User Fee Act. TLANDO® was granted tentative approval from the FDA as a twice-daily...

Read More

Business Insights

SIMULATIONS PLUS HOSTS 2ND ANNUAL PHARMACOMETRICS WORKSHOP

Simulations Plus, Inc. | July 04, 2022

news image

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced record-setting attendance and virtual content delivery for the 2022 Pharmacometrics Spring School using MonolixSuite™. New for 2022 was the introduction of the “NCA, bioequivalence, and beyond! Spring School” course using PKanalix™. Both workshops were held in March 2022. This year’s Spring Schools fo...

Read More

ASHP DEMANDS MORE MANUFACTURING OF VENTILATOR DRUGS FOR COVID-19

PharmaNewsIntelligence | April 07, 2020

news image

ASHP recently urged the Trump administration to take action to address shortages of supportive ventilator drugs as the number of confirmed COVID-19 cases continues to rise. The American Society of Health-System Pharmacists (ASHP) recently called on the Trump Administration to address shortages of supportive ventilator drugs as COVID-19 continues to infect more patients. In an official letter to Vice President Mike Pence, ASHP requested the administration release drugs from the Strategic Na...

Read More
news image

Pharma Tech

VEEVA DEVELOPMENT CLOUD SIMPLIFIES DRUG DEVELOPMENT IN THE INDUSTRY

Veeva Systems | May 21, 2021

A growing number of life sciences companies are adopting Veeva Development Cloud applications from Veeva Systems in an industrywide shift to streamline drug development. quite 650 companies use Veeva Development Cloud applications today, and quite 250 are leveraging multiple Veeva Vault applications across functional areas to enable and connect drug development and manufacturing teams. Veeva Development Cloud brings together suites of unified applications for clinical, regulatory,...

Read More
news image

Pharmacy Market

ANTARES PHARMA ANNOUNCES FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO®

Antares Pharma, Inc. | February 04, 2022

Antares Pharma, Inc. a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted its New Drug Application resubmission for TLANDO®, an oral treatment for testosterone replacement therapy. The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March 28, 2022, under the Prescription Drug User Fee Act. TLANDO® was granted tentative approval from the FDA as a twice-daily...

Read More
news image

Business Insights

SIMULATIONS PLUS HOSTS 2ND ANNUAL PHARMACOMETRICS WORKSHOP

Simulations Plus, Inc. | July 04, 2022

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced record-setting attendance and virtual content delivery for the 2022 Pharmacometrics Spring School using MonolixSuite™. New for 2022 was the introduction of the “NCA, bioequivalence, and beyond! Spring School” course using PKanalix™. Both workshops were held in March 2022. This year’s Spring Schools fo...

Read More
news image

ASHP DEMANDS MORE MANUFACTURING OF VENTILATOR DRUGS FOR COVID-19

PharmaNewsIntelligence | April 07, 2020

ASHP recently urged the Trump administration to take action to address shortages of supportive ventilator drugs as the number of confirmed COVID-19 cases continues to rise. The American Society of Health-System Pharmacists (ASHP) recently called on the Trump Administration to address shortages of supportive ventilator drugs as COVID-19 continues to infect more patients. In an official letter to Vice President Mike Pence, ASHP requested the administration release drugs from the Strategic Na...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us